The latest NSCLC guideline 2021 V2 edition issued by the national comprehensive cancer network (NCCN) indicated that genes associated with targeted therapy of NSCLC include EGFR, KRAS, ALK, ROS1, MET, BRAF, RET, and NTRK [47]. This evidence concerns the gene EGFR and cancer.